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Materials and Methods 
 
Antibodies and Reagents 
Antibodies used for immunocytochemistry, immunohistochemistry and/or western blot 
included: EGFRvIII (Dako), EGFR (Millipore), p-EGFR
1086
 (Invitrogen), p-S6
235/236 
(Cell 
Signaling), p-AKT
473
 (Cell Signaling), p-ERK
202/204
 (Cell Signaling), ZO-1 (Cell 
Singaling), ZEB-1 (Cell Signaling), N-Cadherin (Cell Signaling), Vimentin (Cell 
Signaling), B-Catenin (Cell Signaling), Actin (Sigma) and Ki67 (Dako).   
 
Cell Culture Conditions 
Cell culture consisted of neurosphere culturing conditions consisting of DMEM/F12 
(Gibco), B27 (Invitrogen), Glutamax (Invitrogen) supplemented with Heparin (Sigma), 
EGF (20ng/mL, Sigma) and FGF (20ng/mL, Sigma) added every 3 days. Generation of 
erlotinib resistant (ER) neurospheres consisted of continuous erlotinib treatment 
(GBM39: 5µM, 60 days; HK296 and GBM6: 1µM, 30 days) with fresh erlotinib added 
every 7 days. Assessment of erlotinib resistance was determined through comparing 
sensitivity with vehicle control (DMSO) by WST-1 Assay (Promega) and Annexin V/PI 
staining for apoptosis induction (BD Biosciences).  
 
Microfluidic Chip Fabrication 
The microfluidic cell array chip was fabricated as previously described (1).  Briefly, the 
microfluidic chip for single cell characterization consists of 12-24 individual channels at 
a width of 50µm and 8mm long at a height of 120 µm.  This design was incorporated on a 
silicon wafer through soft lithography methods. Chip fabrication consisted of adding 
polydimethylsilloxane (PDMS), a semipermeable polymer, to the wafer, where it was 
subsequently allowed to cure at 80C overnight. The chip was then removed from the 
mold where holes, which matched the circumference of a standard 20uL pipette tip, were 
punched to form the inlet and outlet of each individual channel.  Finally, the PDMS chip 
was plasma treated where it was then attached to a cover slip that was prewashed with 
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1M HCl overnight at 37°C. The assembled chip was then baked overnight at 80C and 
coated with 100ug/mL poly-D-lysine (Millipore) in PBS overnight at 4°C.    
 
Phase II lapatinib clinical trial 
Details of the phase II lapatinib trial have been described previously (2, 3).  Briefly, the 
North American Brain Tumor Consortium (NABTC) trial 04-01 titled “A biomarker and 
Phase II study of GW572016 (lapatinib) in recurrent malignant glioma” enrolled 
consented patients from University of California at Los Angeles (UCLA), University of 
California at San Francisco, Dana- Farber Cancer Center, Memorial Sloan Kettering 
Cancer Center, University of Pittsburgh, Neuro-oncology branch of National Institutes of 
Health, University of Wisconsin, and Duke University. Adult patients who had a 
Karnofsky performance score (KPS) equal to or greater than 60 and were candidates for 
surgical resection were eligible for this study.  Patients were administered 750 mg of 
lapatinib orally twice a day (BID) for 7 to10 days (depending on whether treatment 
interval fell over a weekend) before surgery, the time to steady state. Blood and tissue 
samples were obtained at the time of resection. After recovery from surgery, patients 
resumed lapatinib treatment at the neoadjuvant dose of 750 mg BID until clinical or 
radiographic evidence for tumor progression was found. Patients with pre and post 
lapatinib samples available, scored positive for EGFRvIII and PTEN at initial biopsy (as 
determined by immunohistochemistry), and demonstrated a decrease in phospho-EGFR 
staining (to demonstrate pharmacodynamics) were included for this study (n=6).  Patients 
1, 2, 3, 4, 5 and 6 correspond to E50153, E50038, E50034, E09355, E09333, and E50031 
respectively in Vivanco et. al.  Intratumoral lapatinib levels for each patient were 
reported Vivanco et. al.   
 
Human Tumor and GBM Xenograft Specimens 
The serially-propagated GBM39 xenograft has been previously described (4).  Briefly, 
surgically resected tissue from a GBM patient at the Mayo Clinic, Rochester, MN was 
mechanically digested and temporarily cultured in vitro for lentiviral infection of firefly 
luciferase (ff-LUC).  Transduced cells were then collected and mixed 1:1 with matrigel 
and injected subcutaneously in immunocompromised mice. Once tumors were 
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established, samples were either archived or propagated in vivo through digestion and re-
injection. For low passage patient-derived GBM neurospheres, all patients were 
consented with approved Institutional Review Board from UCLA. Human brain tumor 
specimens and mouse xenografts were digested into single cell suspensions through 
enzymatic digestion methods.  Specifically, 12500 U of Collagenase II (Worthington 
Biochemical Corp.) and 12500 U of Collagenase IV (Worthington Biochemical Corp.) 
were prepared in serum-free Dulbecco’s Modified Eagle’s medium (DMEM, Gibco).  
Subsequently, minced tumor samples was added to the mixture and shaken for three 
hours at 140 RPM at 37° C.  The digested samples were then passed through a 40µm 
filter and centrifuged at 400g for 5 min. Purified pelleted cells were resuspended in 
serum-free DMEM/F12 (Invitrogen) and loaded on chip or placed in neurosphere 
culturing conditions containing DMEM/F12, B27 (Invitrogen), Glutamax (Invitrogen) 
supplemented with EGF (Sigma), FGF (Sigma) and Heparin (Sigma).   
 
Microfluidic Chip Immunocytochemistry 
All samples were prepared at a concentration of 1.0x10
6
 cells/mL. Three microliters of 
the cell suspensions were then loaded onto the poly-D lysine coated microfluidic chip 
through a standard 20µL pipette.  The chip was placed at 37° C for 5 min to allow the 
cells to adhere inside the microfluidic chip.  For fixation, 4% paraformaldyde (Sigma) 
was added to the channels of the chip containing the adherent cells and allowed to fix 15 
min.  Following three PBS washes, cells were subsequently permeabilized with .3% 
Triton X-100 (Sigma) for 10 minutes, followed by three additional PBS washes.  Cells 
were then blocked in 10% normal goat serum for 30 minutes.  Antibodies used for 
immunocytochemistry include: EGFRvIII (Dako), EGFR (Millipore), p-EGFR
1086
 
(Invitrogen), p-S6
235/236 
(Cell Signaling), p-AKT
473
 (Cell Signaling) and Ki67 (Dako).  To 
achieve same species antibody multiplexing, all antibodies were primary labeled using 
Zenon Immunolabeling Technology (Invitrogen).  Desired cocktails of various antibodies 
were diluted in 10% normal goat serum and incubated in the microfluidic chip for 1 hour.  
Following three PBS washes, cells were counterstained with DAPI (Invitrogen).  For 
TUNEL immunoflourescence staining, prior to primary antibody incubation, cells within 
the microfluidic channels were analyzed for apoptosis using the In Situ Cell Death 
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Detection Kit, TMR red, following the manufacturer’s protocol (Roche). Cellular 
analysis was done with Metamorph Software (Molecular Devices, ver 7.5.6.0) using the 
Multi-Wavelength Cell Scoring module.  For each analysis, at least 1000 cells were 
quantified.   
 
Giemsa-Banded (G-band) Metaphase analyses and Fluorescence in situ 
Hybridization (FISH) 
GBM39 naïve, erlotinib resistant (ER), and erlotinib resistant drug removed (DR) 
neurospheres grown in neurosphere culturing conditions were subcultured in in-situ 
dishes for 24-48 hours before using routine cytogenetics procedures of harvesting, 
fixation and obtaining metapahse preparations. Chromosomal analyses were performed 
by G-banding using trypsin and Giemsa (GTG) at approximately 400 - 450 band level. 
Twenty well-spread metaphases from each of the three cell-lines were analyzed to 
identify the extrachromosomal elements and other marker chromosomes. Fluorescence in 
situ hybridization (FISH) was performed using commercially available fluorescently 
labeled dual-color EGFR (red)/CEP 7(green) and MDM2 (red)/CEP 12 (green) probe sets 
form Abbott-Molecular, IL. USA. The FISH hybridization and analyses were performed 
on both metaphase an interphase preparations from the three cell-lines and formalin fixed 
paraffin tissue sections,  following the manufacturer's suggested protocols. The cells were 
counterstained with DAPI and the red and green fluorescent probe signals were 
simultaneously observed and imaged under a Zeiss (Axiophot) Fluorescent Microscope 
equipped with dual- and triple-color filters. 
 
18
F-Fluorodeoxyglucose (FDG) uptake assay  
For in vitro 
18
F-FDG uptake assays, freshly sorted EGFRvIII
High
 and EGFRvIII
Low
 cells 
GBM39 neurospheres were loaded into one of four microchannels within a microfluidic 
chip, which was similar to that reported previously (5, 6).  Each microchannel contained 
four separate microchambers.  Upon cell loading, each of the four microchambers 
contains between 20 and 61 cells, the numbers of which are counted by microscopic 
imaging through the transparent elastomer material of the microfluidic chip.  The bottom 
surfaces of the microchambers are coated with fibronectin to support cell attachment, and 
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are separated by 50 micrometers from a Β-camera.  This camera uses a position sensitive 
avalanche photodiode to detect charged particles.   After sorting, a cell suspension in cell 
culture medium with a concentration of 3×10
6
 cells/ml was pipetted into the 
microchannel inlets.  The microchannels were gently flushed three times with flowing 
PBS solution to remove unattached cells and to thoroughly deplete residual glucose in the 
microchannels. 
18
F-FDG (radioactivity 1mCi/mL) in PBS was then loaded into the cell 
chambers by flowing for 30 sec to completely replace PBS.  The whole microchip placed 
in a CO2 incubator at 37 °C for 30 min, before washing by PBS two times for 30 sec.  
The chip was then imaged with the B-camera.  The radioactivity in each microchamber 
was normalized against the number of cells in that microchamber for the B-camera image 
The data of Fig. 1E represents the average of two separate microchip experiments, each 
one of which yielded between 4 and 8 separate assays for each phenotype.   
 
Xenograft Model 
In vivo subcutaneous serial passaging of GBM39 was described previously (4, 7).  For in 
vivo erlotinib (Chemietek) experiments, single-cell suspensions of digested GBM39 
xenografts were prepared at a concentration of 1×10
6 
cells/ml in a solution of 
DMEM/F12 containing no additives and Matrigel (BD Biosciences). Two-hundred 
microliters of this solution was injected into the flanks of NOD-scid IL2Rgamma
null  
(NSG, Jackson Laboratories) mice and then randomly grouped into either vehicle/placebo 
(n=4), short-term erlotinib (n=4), or continuous erlotinib treatment (n=4).  Tumor growth 
was monitored with calipers measuring the perpendicular diameter of each tumor.  
Erlotinib was administered daily via oral gavage at a dose of 150mg/kg, which has 
previously shown to be elicit a response in GBM39 with low toxicity (4).  All 
experiments were conducted after approval by the Chancellor’s Animal Research 
Committee of UCLA. 
 
FACS and Flow Cytometry 
Single cell suspensions from tumor xenografts were obtained and were incubated with a 
mixture of antibodies including anti-mouse CD45-APC (BD), anti-mouse H2kd-APC 
(eBioscience) for mouse cell exclusion and EGFRvIII-Alexa 488 in 5% FBS PBS for 20 
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min on ice.  In addition, propidium iodide was used for dead cell exclusion.  For cell 
sorting, the Aria II flow cytometer was used (BD Biosciences).  Acquisitions were 
performed on a BD LSRII.  All data was analyzed using FlowJo (Tree Star) software. 
 
Western Blotting 
Western blotting was conducted as described previously (2). Cells or tissue samples were 
homogenized and lysed in RIPA Lysis Buffer containing Tris (10 mmol/liter; pH 7.4), 
NaCl (100 mM), EDTA (1 mM), EGTA (1 mM), NaF (1 mM), Na4P2O7 (20 
mM),Na3VO4 (2mM), 0.1% sodium dodecyl sulfate, 0.5% sodium deoxycholate, 1% 
Triton X-100, 10% glycerol, leupeptin (10 µg/ml), aprotinin (60 μg/ml), and 
phenylmethanesulfonyl fluoride (1 mM). Equal amounts of protein extracts were 
separated by 8 or 10% SDS–polyacrylamide gel electrophoresis and then transferred to a 
polyvinylidene difluoride membrane (Bio-Rad Laboratories). The membrane was 
blocked for 1 hour in tris-buffered saline containing 0.1% Tween 20 and 5% nonfat milk 
and then probed with desired primary antibodies overnight at 4°C, followed by secondary 
antibodies conjugated to horseradish peroxidase (HRP). The immunoreactivity was 
revealed by use of an ECL kit (Amersham Biosciences). 
 
Immunohistochemistry 
Paraffin-embedded tissue blocks were sectioned using the UCLA Pathology 
Histology and Tissue Core Facility. Immunohistochemical staining (IHC) and scoring 
was performed as previously described (2, 8-10). Slides were counterstained with 
hematoxylin to visualize nuclei. Paraffin-embedded tissue sections underwent 
immunohistochemical analysis and quantitative image analysis using Soft Imaging 
System software was performed. We have previously demonstrated the utility of this 
quantitative method for measuring drug-specific effects in paraffin-embedded tissue 
samples from GBM patients enrolled in clinical trials with targeted agents (2, 8-10). 
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Cell Death and Proliferation Assay 
Relative cell proliferation was determined using the WST-1 Cell Proliferation Assay Kit 
and absorbance was measured with a microplate reader (Bio-Rad) at 420 to 480.  Cell 
death was determined by trypan blue exclusion assay. 
 
 
 
Mapping EGFRvIII deletions in glioblastoma extrachromosomal DNA 
Extrachromosomal DNA was isolated from glioblastoma neurospheres by a modified Hirt 
procedure (11) and was digested with BamH1 and probed by Southern Blotting with an 
exon 8 probe to determine the size of the cell-type specific EGFRvIII fragments 
generated by BamH1. Given that there are 14 BamH1 sites in intron 1, one site in intron 6 
and one in intron 8 just downstream on exon 8, we reasoned that the EGFRvIII deletions 
could be mapped by sequencing PCR products obtained by combining an intron 8 anchor 
primer adjacent to the BamH1 site with forward primers that anneal adjacent to each of 
the 14 BamH1 sites in intron 1. The chromosome 7 coordinates for BamH1 site just 
upstream on exon 1 was 55070485. Those of 14 BamH1 sites in intron 1 were 55105839, 
55107896, 55117201, 55119776, 55120751, 55124472, 55132138, 55146472, 55151633, 
55178383, 55187313, 55192289, 55192343 and 55198500. The BamH1 site at intron 6 
was at 55220852 and the BamH1 site just downstream on exon 8 was located at 
55224167. Only those primer sets yielding a product of similar size to the bands obtained 
by Southern blot were sequenced.  Forward primers (Fig. 3) were:  
1: CTATTGGACACAACTGGAAGAAG (Chromosome 7 coordinates, 55070463-
55070485),  
2: TGGAGCCACAGTACATTCAGGTG (55105817-55105839),  
3: GCTCTGTGGAGGTCAGAAGGAG(55107875-55107896), 
4:ACATCTCTGGAGAAGGAAATGG(55117180-55117201),  
5:GGTGGAGGATGAGAGGACCCTG(55119755-55119776),  
6:TAGCACCCTTCAAATGTTTTAG(55120730-55120751),  
7:AAGATCTGGGTGTTTTCATTGG(55124452-55124473),  
8:AGTATCCAGACATCCAGAAAGG(55132118-55132139), 
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9:GAGATGGTTTGGGCAGCCCGCG(55146451-55146472), 
10:ACATATAGGTTAGCAAGATTGG(55151613-55151634), 
11:TTCCATTCTGTTTCCTGTTCGG(55178363-55178384), 
12:GTTCAAAAAAAGGTATCCCAAGG(55187292-55187314), 
13:GGGCATAACTGATCCAAAGGATG(55192267-55192289), 
14:CCAGCCAAGATGACAACAGTCAG(55192321-55192343), 
15:TCAGCTGTATGTGCCCCGCACAG(55198478-55198500),   
16:CTGGGTTAGGGCCTCCTGACACG (55220830-55220852).  
The anchor primer was designed at the BamH1 site in intron 8 (primer 17): 
GGATTAAGAATAGCTAGGGATCC (55224184-55224162). PCR products of the 
expected size were obtained from GBM6, GBM39 and HK296 by combining the anchor 
primer and forward primers 10, 13 and 5, respectively using platinum Taq DNA 
Polymerase High Fidelity (Life Technologies, Carlsbad, CA). PCR products were cloned 
using the TOPO TA Cloning Kit (Life Technologies), sequenced and aligned to the 
EGFR gene using the UCSC Genome Browser (Feb 2009 GRCH/hg19 Assembly). 
Primer pairs 13/17 and 14/17 span regions that are 32kb apart in wild type 
EGFR, but only slightly over 4kb in EGFRvIII, thus amplifying EGFRvIII, but not wild 
type EGFR. Primers 15 and 16 are both deleted in EGFRvIII, but maintained in wild type 
EGFR. 
 
Quantitative PCR analysis of EGFRvIII extrachromosomal DNA 
Glioblastoma neurosphere cells, 0.5x10
6 
to 1.0x10
6
 cells, were pelleted; lysed and 
extrachromosomal DNA was isolated as above. Triplicate qPCR reactions containing 1 
ng of DNA were run on a CFX96
TM
 Real Time System (Bio-Rad, Hercules, CA) with the 
following reaction conditions: 95ºC for 5 min, 40 cycles of 95ºC for 15s and 60ºC for 
30s. Primer pairs for glioblastoma cell-specific EGFRvIII mutants were designed to span 
the EGFR deleted regions. The data was normalized to mitochondrial DNA and the 
relative amount of EGFR extrachromosomal DNA was determined using 2
-∆
Ct formula. 
Primers for mitochondrial DNA were, forward: CTCAAATGGGCCTGTCCTTG and 
reverse: GCTTTGGGTGCTAATGGTGG. Primers for glioma cell-specific EGFR 
mutants were, GBM39: GGGTCTCATTAGGAAGGAGAGG and 
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TCTGTGAACCATCTGCTCTTGG, HK296: CTTTGATGTCCCTGCCTGAG and 
CTGTGTCATCACTGTGGCAC, GBM6: TGTGTAGCGGGTACCTTCTG and 
TGTGGCTGCTGGATGAGTG.  
 
MDM2 PCR 
To detect the presence of MDM2 amplification, five nanograms of Hirt DNA from 
GBM39 naive, erlotinib resistant (ER) and drug removed (DR) cells was PCR amplified 
with MDM2 primers (forward:   CCCAGGTTAAGAACTTCTGCACTAG reverse: 
AGGCATAGTGGTACAAGCCTGTAG) mapping to a region of intron 1 that yielded a 
960 bp product.  One hundred nanograms of fibroblast genomic DNA was used as 
positive control. 
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Fig. S1. 
Firefly-luciferase labeling identifies tumor cells, enabling assessment of tumor 
specific EGFRvIII staining (A) Co-immunofluorescence of Firefly-luciferase (f-LUC, 
Red) and EGFRvIII (Green) on MIC chip of GBM39 naïve single cells shows tumor 
populations containing EGFRvIII
High
 and EGFRvIII
Low
 cells. (B) Quantification from 
MIC staining of   EGFRvIII
High 
and EGFRvIII
Low
 cells within the Firefly-luciferase 
positive population. Quantification based on analysis of >1000 cells. Values are mean ± 
SEM.  
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Fig. S2 
MIC Chip assay quantification of signaling pathways in EGFRvIII
High
 and 
EGFRvIII
Low 
subpopulations Top: MIC characterization of % positive for Ki67 and 
TUNEL for the EGFRvIII
High
 and EGFRvIII
Low
 subpopulations.  * P<0.005 from 
unpaired t test. Bottom: MIC analysis of signal intensity for phospho-EGFR (Y1086), 
phospho-AKT (s473), and phospho-S6 (s235/236).  The final intensity was determined 
following background subtraction (1) .  Statistics are derived from MIC quantification of 
>1000 cells. * P<0.005, ** P<0.0001 from unpaired t test. 
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Fig. S3 
IHC staining of Ki67, TUNEL and pEGFR in GBM39 xenograft model of acquired 
erlotinib resistance. (A) Ki67 IHC and quantification of vehicle, response and resistant 
tumor samples. Values are mean± SEM. * P< 0.001 ** P < 0.01 from unpaired t test. (B) 
Trypan blue exclusion assay on vehicle, response and resistant tumor samples. Values are 
mean ± SEM. *P < 0.01 from unpaired t test. (C) MIC analysis of pEGFR (Y1086) 
intensity in vehicle, response and resistant samples. Values are mean ± SEM. * P<0.01 
** P<0.0001 from unpaired t test.  
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Fig. S4 
Effect of erlotinib on EGFRvIII High/Low ratio in an independent patient-derived 
GBM neurosphere model. Top: Heterogeneity of EGFRvIII expression by 
immunohistochemistry in patient biopsy tissue in which HK296 was derived. Bottom: 
MIC quantification of EGFRvIII in HK296 patient-derived neurospheres shows 
enrichment for EGFRvIIILow cells following three passages of erlotinib treatment. 
Cellular composition statistics derived from MIC quantification of >1000 cells. Values 
are mean ± SEM * P<0.05 from unpaired t test 
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Fig. S5  
 
Erlotinib prevents upregulation of EGFRvIII expression. (A) FACS-sorted 
EGFRvIII
Low
 GBM39 cells were analyzed for EGFRvIII expression by immunoblot 
analysis immediately post-sort, or after 24 hours with vehicle or erlotinib treatment 
(5µM). (B) FACS analysis of EGFRvIII expression after 3, 6, 12, 24 days of erlotinib or 
vehicle (Veh) in GBM39 naïve cells. (C) Annexin V staining from (B).  
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Fig. S6 
 
Geimsa Banding on GBM39 naïve, ER and DR cells. Partial Giemsa banded 
metaphases from naïve, erlotinib resistant (ER) and drug removed (DR) cells showing 
abundant extrachromosomal DNA in all conditions (blue arrows).
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Fig. S7 
 
EGFR FISH on interphase cells of GBM39 cells. Representative images from dual-
color FISH (EGFR (red)/CEP7 (green)) on GBM39 naïve, erlotinib resistant (ER) and 
drug removed cells (DR).  Nuclei counterstained with DAPI. 
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Fig. S8 
 
Analysis of MDM2 in erlotinib resistant GBM cells. (A) FISH analysis of a metaphase 
spread using MDM2 (red) and chromosome 12 centromere probes (green) reveals 
abundant MDM2+ DMs. (B) PCR amplification of a 960 bp region from intron 1 of 
MDM2 using 5 ng of low molecular weight DNA isolated from naïve, erlotinib resistant 
and drug removed GBM39 cells. 100 ng of normal genomic human DNA is used as a 
control.  
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Fig. S9 
 
Metaphase FISH of DAPI stained chromosomes using EGFR (red) and chromosome 
7 (green) probes reveals “marker” chromosomes characterized by many copies of 
EGFR, but no chromosome 7 centromere. (A) Treatment naïve, (B) erlotinib resistant 
(ER) and (C) erlotinib resistant drug removed (DR) cells. (D) Another region as a 
positive control for CEP7 FISH probe in ER cells. 
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Fig. S10 
 
Primer design for qPCR of extrachromosomal EGFRvIII in GBM6, GBM39 and 
HK296. Primer sequences were designed to the unique breakpoints adjacent to exons 2-7 
within EGFR for GBM6, GBM39, and HK296 specific for EGFRvIII. 
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Fig. S11 
 
GBM patient-derived neurospheres are re-sensitized to erlotinib following drug 
removal of erlotinib resistant cultures.  (A) Annexin V staining of GBM39 treatment 
naïve, erlotinib resistant (ER) and erlotinib resistant drug removed (DR, 30 days) cells 
following 72 hrs of erlotinib treatment (5µM).  Values are mean ± SEM. * P< 0.005 from 
unpaired t test. (B) Trypan blue exclusion assay of GBM6 and HK296 treatment naïve, 
erlotinib resistant (ER) and erlotinib resistant drug removed (DR, 72 hrs) cells following 
72 hrs of erlotinib treatment (GBM39: 5µM, GBM6 and HK296: 1µM ).  Values are 
mean ± SEM. * P<0.0001 from unpaired t test. 
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Fig. S12 
 
Lapatinib reduces EGFRvIII extrachromosomal levels in GBM39, GBM6 and 
HK296 neurospheres.  (Top) Immunoblot of GBM39, GBM6 and HK296 following 48 
hrs treatment with 1.5µM lapatinib. (Bottom) qPCR analysis of extrachromosomal 
EGFRvIII levels in GBM39, GBM6, and HK296 cells following treatment with 0.5 µM 
lapatinib for 7 days followed by 1.5µM for 7 days.  *P <0.0001, ** P <0.001, *** P 
<0.01.
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Fig. S13 
 
EGFRvIII extrachromosomal levels in FACS sorted EGFRvIII
High
 and 
EGFRvIII
Low
 cells from GBM39 naïve tumor cells.  GBM39 naïve neurospheres were 
FACS sorted for EGFRvIII
High
 and EGFRvIII
Low 
subpopulations.  Sorted populations 
were analyzed for EGFRvIII protein (left) and EGFRvIII extrachromosomal levels by 
qPCR (right).   
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Fig. S14 
 
Irreversible upregulation of ZEB-1 in GBM39 erlotinib resistant (ER) and drug 
removed (DR) cells.  Immunoblot of GBM39 naïve, erlotinib resistant (ER) and drug 
removed (DR) for markers of epithelial–mesenchymal transition. 
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